Nucleus Pulposus-Targeting Nanocarriers Facilitate Mirna-Based Therapeutics for Intervertebral Disc Degeneration

Adv Healthc Mater. 2023 Nov;12(28):e2301337. doi: 10.1002/adhm.202301337. Epub 2023 Sep 8.

Abstract

Intervertebral disc degeneration (IDD) is a common cause of low back pain. Understanding its molecular mechanisms is the basis for developing specific treatment. To demonstrate that miR-22-3p is critical in the regulation of IDD, miRNA microarray analyses are conducted in conjunction with in vivo and in vitro experiments. The miR-22-3p knockout (KO) mice show a marked decrease in the histological scores. Bioinformatic analysis reveals that miR-22-3p plays a mechanistic role in the development of IDD by targeting SIRT1, which in turn activates the JAK1/STAT3 signaling pathway. This is confirmed by a luciferase reporter assay and western blot analysis. Therapeutically, the delivery of miR-22-3p inhibitors and mimics through the synthesized nanoparticles in the IDD model alleviates and aggravates IDD, respectively. The nanocarriers enhance transportation of miR-22-3p to nucleus pulposus cells, thus enabling the in vivo inhibition of miR-22-3p for therapeutic purposes and consequently promoting the development of miRNA-specific drugs for IDD.

Keywords: IDD; microRNAs; nanoparticle; nucleus pulposus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / genetics
  • Intervertebral Disc Degeneration* / drug therapy
  • Intervertebral Disc Degeneration* / genetics
  • Mice
  • Mice, Knockout
  • MicroRNAs* / genetics
  • MicroRNAs* / metabolism
  • Microarray Analysis
  • Nucleus Pulposus* / metabolism
  • Nucleus Pulposus* / pathology
  • Signal Transduction

Substances

  • MicroRNAs